CD40/CD28 co-stimulation boosts CAR-T activity in solid tumors
A preclinical CAR-T strategy combining CD40 and CD28 co-stimulation reprogrammed solid-tumor immunity, improved persistence, and enhanced anti-PD-1 synergy.
Therapeutics, diagnostics and evidence shaping cancer care.
Therapeutics, diagnostics and evidence shaping cancer care.